Back to gene therapy: bringing the EU regulation into the future

Area of Science:

• Pharmaceutical Science
• Biotechnology
• Regulatory Science

Background:

• The European framework for Advanced Therapy Medicinal Products (ATMPs), established in 2007, requires modernization.
• Scientific and technological advances, especially in gene therapeutics, manufacturing, and delivery, have outpaced the current regulatory structure.
• Limitations are evident for novel gene therapies with distinct mechanisms of action.

Purpose of the Study:

• To discuss reducing regulatory uncertainty for gene therapies with novel mechanisms of action.
• To rationalize regulatory support and incentives for complex ATMPs.
• To inform scientific and regulatory discussions on evolving gene therapeutic products.

Main Methods:

• Literature review and analysis of the current European ATMP regulatory framework.
• Identification of limitations in qualifying gene therapies with new mechanisms of action.
• Exploration of strategies for rationalizing regulatory support and incentives.

Main Results:

• The 2007 ATMP framework faces challenges with innovative gene therapeutics (e.g., CRISPR/Cas9-RNA complexes).
• Regulatory uncertainty exists for products that edit host genomes or regulate gene expression.
• Current frameworks may not adequately support complex manufacturing processes and novel delivery systems.

Conclusions:

• The European ATMP regulatory framework needs adaptation to accommodate scientific advancements in gene therapy.
• Clearer guidelines are required for qualifying gene therapies with novel mechanisms of action.
• Streamlined regulatory support and incentives are crucial for complex gene-based medicines.